TBPH लाइव सिग्नल्स | Getagraph.com के साथ लाभ को अधिकतम करें

बेचें 113762 min ago

@ $8.45

जारी किया गया: 14 Feb 2024 @ 20:00

वापसी: 11.36%

पिछला सिग्नल: Feb 14 - 00:12

पिछला सिग्नल: खरीदें

वापसी: 1.38 %

Live Chart Being Loaded With Signals

Commentary (3 May 2024 @ 20:00):

Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia...

Stats
आज की मात्रा	31 030.00
औसत मात्रा	404 030
बाजार मूल्य	453.23M
EPS	$0 ( 2024-02-26 )
अगली कमाई की तारीख	( $-0.190 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-9.41
ATR14	$0.0270 (0.29%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-02	Winningham Rick E	Buy	300 000	Ordinary Shares
2024-04-02	Sawaf Aziz	Buy	100 000	Ordinary Shares
2024-04-02	Miller Aine	Buy	37 500	Ordinary Shares
2024-04-02	Grimaud Brett A.	Buy	100 000	Ordinary Shares
2024-04-02	Farnum Rhonda	Buy	37 500	Ordinary Shares

INSIDER POWER
47.04
Last 95 transactions
Buy: 1 532 401 \| Sell: 647 888

मात्रा सहसंबंध

लंबा: -0.12 (neutral)

छोटा: 0.74 (moderate)

Signal:(50.418) Neutral

Theravance Biopharma Inc सहसंबंध

10 सबसे अधिक सकारात्मक सहसंबंध
NETE	0.889
RAVN	0.857
SRAC	0.835
LWAC	0.803

10 सबसे अधिक नकारात्मक सहसंबंध
SVAC	-0.893
PAIC	-0.881
TLGT	-0.869
GOODM	-0.82

क्या आप जानते हैं?

कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।

कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।

Theravance Biopharma Inc सहसंबंध - मुद्रा/वस्त्र

-0.01
( neutral )

-0.17
( neutral )

0.00
( neutral )

-0.13
( neutral )

-0.47
( neutral )

-0.49
( neutral )

Theravance Biopharma Inc वित्तीय

Annual	2023
राजस्व:	$57.42M
सकल लाभ:	$51.37M (89.46 %)
EPS:	$-1.000

FY	2023
राजस्व:	$57.42M
सकल लाभ:	$51.37M (89.46 %)
EPS:	$-1.000

FY	2022
राजस्व:	$51.35M
सकल लाभ:	$44.76M (87.17 %)
EPS:	$-1.260

FY	2021
राजस्व:	$55.31M
सकल लाभ:	$0.00 (0.00 %)
EPS:	$-2.87

Financial Reports:

No articles found.

Theravance Biopharma Inc

Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also include Izencitinib, a gut-selective pan-janus kinase (JAK) inhibitor that is in Phase IIb/III clinical trials for the treatment of rheumatoid arthritis, myelofibrosis, and ulcerative colitis, as well as for a range of inflammatory intestinal diseases, including ulcerative colitis and Crohn's disease. In addition, the company's product portfolio comprise Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; Nezulcitinib, a lung-selective, nebulized JAK inhibitor, which is in Phase II clinical development for the potential treatment of hospitalized patients with acute lung injury caused by COVID-19; Inhaled ALK5i, a potential inhaled anti-fibrotic agent that is in Phase I for the treatment of idiopathic pulmonary fibrosis; and TD-5202, an investigational, orally administered, gut-selective, irreversible JAK3 inhibitor that is in Phase I clinical study for treatment of inflammatory intestinal diseases. Further, it offers TRELEGY for the treatment of COPD and asthma; Velusetrag, an oral and investigational medicine for gastrointestinal motility disorders; and Selective 5-HT4 Agonist for treatment of gastrointestinal motility disorders. It has a licensing and collaboration agreements with Pfizer Inc., Viatris Inc., Janssen Biotech, Inc., Alfasigma S.p.A, and Takeda Pharmaceutical Company Limited. Theravance Biopharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.